Dening Tahnee J, Rao Shasha, Thomas Nicky, Prestidge Clive A
School of Pharmacy and Medical Sciences, University of South Australia, City East Campus, Adelaide, South Australia 5001, Australia.
School of Pharmacy and Medical Sciences, University of South Australia, City East Campus, Adelaide, South Australia 5001, Australia.
Int J Pharm. 2017 Jun 30;526(1-2):95-105. doi: 10.1016/j.ijpharm.2017.04.063. Epub 2017 Apr 27.
Lipid-based formulations (LBFs) are a popular strategy for enhancing the gastrointestinal solubilization and absorption of poorly water-soluble drugs. In light of this, montmorillonite-lipid hybrid (MLH) particles, composed of medium-chain triglycerides, lecithin and montmorillonite clay platelets, have been developed as a novel solid-state LBF. Owing to the unique charge properties of montmorillonite, whereby the clay platelet surfaces carry a permanent negative charge and the platelet edges carry a pH-dependent charge, three model poorly water-soluble drugs with different charge properties; blonanserin (weak base, pKa 7.7), ibuprofen (weak acid, pKa 4.5) and fenofibrate (neutral), were formulated as MLH particles and their performance during biorelevant in vitro lipolysis at pH 7.5 was investigated. For blonanserin, drug solubilization during in vitro lipolysis was significantly reduced 3.4-fold and 3.2-fold for MLH particles in comparison to a control lipid solution and silica-lipid hybrid (SLH) particles, respectively. It was hypothesized that strong electrostatic interactions between the anionic montmorillonite platelet surfaces and cationic blonanserin molecules were responsible for the inferior performance of MLH particles. In contrast, no significant influence on drug solubilization was observed for ibuprofen- and fenofibrate-loaded MLH particles. The results of the current study indicate that whilst MLH particles are a promising novel formulation strategy for poorly water-soluble drugs, drug ionization tendency and the potential for drug-clay interactions must be taken into consideration to ensure an appropriate performance.
基于脂质的制剂(LBFs)是增强难溶性药物胃肠道溶解和吸收的常用策略。鉴于此,由中链甘油三酯、卵磷脂和蒙脱石粘土片层组成的蒙脱石-脂质杂化(MLH)颗粒已被开发为一种新型固态LBF。由于蒙脱石具有独特的电荷性质,即粘土片层表面带有永久负电荷,片层边缘带有pH依赖性电荷,因此将三种具有不同电荷性质的难溶性模型药物;布南色林(弱碱,pKa 7.7)、布洛芬(弱酸,pKa 4.5)和非诺贝特(中性),制成MLH颗粒,并研究了它们在pH 7.5的生物相关体外脂解过程中的性能。对于布南色林,与对照脂质溶液和硅石-脂质杂化(SLH)颗粒相比,MLH颗粒在体外脂解过程中的药物溶解分别显著降低了3.4倍和3.2倍。据推测,阴离子蒙脱石片层表面与阳离子布南色林分子之间的强静电相互作用是MLH颗粒性能较差的原因。相比之下,载有布洛芬和非诺贝特的MLH颗粒对药物溶解没有显著影响。当前研究结果表明,虽然MLH颗粒是一种有前景的难溶性药物新型制剂策略,但必须考虑药物的电离趋势以及药物与粘土相互作用的可能性,以确保适当的性能。